Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Septerna, Inc. - Common Stock
(NQ:
SEPN
)
24.34
+0.90 (+3.84%)
Streaming Delayed Price
Updated: 2:42 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Septerna, Inc. - Common Stock
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
March 09, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
March 01, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
February 10, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
January 08, 2026
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Participate in 8th Annual Evercore Healthcare Conference
November 25, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
November 10, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Participate in Upcoming Investor Conferences
November 03, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
September 29, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Participate in Upcoming Investor Conferences
August 27, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
August 21, 2025
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
August 11, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present at Jefferies Global Healthcare Conference
May 29, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
May 15, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside
May 14, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
March 27, 2025
From
Septerna, Inc.
Via
GlobeNewswire
SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm
March 18, 2025
From
The Schall Law Firm
Via
Business Wire
Septerna to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025
From
Septerna, Inc.
Via
GlobeNewswire
SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm
February 21, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
February 18, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
January 06, 2025
From
Septerna, Inc.
Via
GlobeNewswire
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 20, 2024
From
Septerna, Inc.
Via
GlobeNewswire
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
October 30, 2024
From
Septerna, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
